Bioxytran (BIXT) 10-Q 13 May 20 2020 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2020	May 12, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	BIOXYTRAN, INC
Entity Central Index Key	0001445815
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		97,031,673
Entity File Number	001-35027
Entity Incorporation State Country Code	NV

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
Current assets:
Cash	$ 43,891	$ 169,628
Other receivable		50,000
Total current assets	43,891	219,628
Total assets	43,891	219,628
Current liabilities:
Accounts payable and accrued expenses	46,346	71,932
Accounts payable related party	116,000	96,000
Convertible notes payable, net of premium and discount	1,718,695	850,983
Total current liabilities	1,881,041	1,018,915
Total liabilities	1,881,041	1,018,915
Commitments and contingencies
Stockholders' equity (deficit):
Preferred stock, $0.001 par value; 50,000,000 shares authorized, nil issued and outstanding
Common stock, $0.001 par value; 300,000,000 shares authorized; 88,231,673 issued and outstanding as of March 31, 2020, and 86,475,673 issued and outstanding as of December 31, 2019	88,232	86,476
Additional paid-in capital	856,418	1,355,542
Accumulated deficit	(2,781,800)	(2,241,305)
Total stockholders' equity (deficit)	(1,837,150)	(799,287)
Total liabilities and stockholders' equity (deficit)	$ 43,891	$ 219,628

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	88,231,673	86,475,673
Common stock, shares outstanding	88,231,673	86,475,673

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses:
General and administrative	$ 266,043	$ 129,625
Total operating expenses	266,043	129,625
Loss from operations	(266,043)	(129,625)
Other income (expense):
Interest expense	(107,730)	(6,887)
Amortization of debt discount	(166,722)	(54,897)
Total other income (expenses)	(274,452)	(61,784)
Net loss before provision for income taxes	(540,495)	(191,409)
Provision for income taxes
NET LOSS	$ (540,495)	$ (191,409)
Loss per common share, basic and diluted	$ (0.01)	$ 0
Weighted average number of common shares outstanding, basic and diluted	87,256,959	85,103,673

Condensed Consolidated Changes

Condensed Consolidated Changes in Stockholders’ Equity (Deficit) (Unaudited) - USD ($)	Common Stock	Additional Paid in Capital Common	Accumulated Deficit	Total
Balance at Dec. 31, 2018	$ 85,104	$ 72,412	$ (382,830)	$ (225,314)
Balance, shares at Dec. 31, 2018	85,103,673
Issuance of warrants		45,361		45,361
Debt premium on convertible note		(343,796)		(343,796)
Debt premium accretion		60,268		60,268
Net loss			(191,409)	(191,409)
Balance at Mar. 31, 2019	$ 85,104	(165,755)	(574,239)	(654,890)
Balance, shares at Mar. 31, 2019	85,103,673
Balance at Dec. 31, 2019	$ 86,476	1,355,542	(2,241,305)	(799,287)
Balance, shares at Dec. 31, 2019	86,475,673
Issuance of warrants		145,438		145,438
Conversion of warrants	$ 750	(750)
Conversion of warrants, shares	750,000
Options issued - 2010 Plan		5,004		5,004
Shares issued - 2010 Plan	$ 656	149,841		150,497
Shares issued - 2010 Plan, shares	656,000
Debt premium on convertible note		(937,007)		(937,007)
Debt premium accretion		104,568		104,568
Shares issued for conversion of principal and accrued interest	$ 350	33,782		34,132
Shares issued for conversion of principal and accrued interest, shares	350,000
Net loss			(540,495)	(540,495)
Balance at Mar. 31, 2020	$ 88,232	$ 856,418	$ (2,781,800)	$ (1,837,150)
Balance, shares at Mar. 31, 2020	88,231,673

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (540,495)	$ (191,409)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Amortization of debt discount, incl. issuance of warrants	166,722	54,897
Stock-based compensation expense	155,501
Changes in operating assets and liabilities:
Other receivable	50,000
Accounts payable and accrued expenses	(8,517)	7,682
Accounts payable related party	20,000	(10,900)
Net cash used in operating activities	(156,789)	(139,730)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes payable	264,000	222,250
Repayment of convertible notes payable	(232,948)
Net cash provided by financing activities	31,052	222,250
Net increase (decrease) in cash	(125,737)	82,520
Cash, beginning of period	169,628	36,411
Cash, end of period	43,891	118,931
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Interest paid	91,362
Income taxes paid
NON-CASH INVESTING & FINANCING ACTIVITIES
Issuance of warrants	145,438	45,361
Debt discount on convertible note	(76,265)	(25,165)
Debt premium on convertible note	(937,007)	(343,796)
Accretion of debt premium to additional paid-in capital	104,568	60,268
Common shares issued for the conversion of principal and accrued interest	$ 34,132

Background and Organization

Background and Organization	3 Months Ended
	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BACKGROUND AND ORGANIZATION	NOTE 1 – BACKGROUND AND ORGANIZATION Business Operations Bioxytran, Inc. (the "Company") is an early-stage pharmaceutical company focused on the development, manufacture and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen to tissues, in a safe and efficient manner. If it is not addressed, lack of oxygen to tissues, or hypoxia, results in necrosis, which is the death of cells comprising body tissue. Necrosis cannot be reversed. Our lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications to include treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. The Company's initial focus is the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. Our novel approach is intended to result in the creation of safe drug alternatives to existing therapies for effectively addressing hypoxic conditions in humans. Our drug development efforts are guided by specialists in co-polymer chemistry and other disciplines, and we intend to supplement our efforts with input from a scientific and medical advisory board whose members are leading physicians. Organization Bioxytan, Inc. was organized on October 5, 2017 as a Delaware corporation, with a taxing structure for U.S. federal and state income tax as a C-Corporation with 95,000,000 authorized common shares with a par value of $0.0001, and 5,000,000 preferred shares with a par value of $0.0001. On September 21, 2019, the Company went under a reorganization in form of a reverse merger and is currently registered as a Nevada corporation with a taxing structure for U.S. federal and state income tax as a C-Corporation with 300,000,000 authorized common shares with a par value of $0.001, and 50,000,000 preferred shares with a par value of $0.001 Basis of Presentation The summary of significant accounting policies presented below is designed to assist in understanding the Company's consolidated financial statements. Such financial statements and accompanying notes are the representations of the Company's management, who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") in all material respects, and have been consistently applied in preparing the accompanying financial statements. The Company has not earned any revenue from operations since inception. The Company chose December 31 st The accompanying unaudited financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted in accordance with such rules and regulations. The information furnished in the interim financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim financial statements be read in conjunction with the Company's audited financial statements and notes thereto included in its Form 10-K for the year ended December 31, 2019. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020. Basic and Diluted Earnings per Share Pursuant to the authoritative guidance, basic net income and net loss per share are computed by dividing the net income and net loss by the weighted average number of common shares outstanding. Diluted net income and net loss per share is the same as basic net income and net loss per share when their inclusion would have an anti-dilutive effect due to our continuing net losses. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Bioxytran, Inc. a Nevada Corporation and its wholly owned subsidiary, Bioxytran, Inc. of Delaware (collectively, the "Company"). All intercompany accounts have been eliminated upon consolidation.

Going Concern and Management's

Going Concern and Management's Liquidity Plans	3 Months Ended
	Mar. 31, 2020
Going Concern and Management's Liquidity Plans [Abstract]
GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	NOTE 2 – GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS As of March 31, 2020, the Company had cash of $43,891 and a negative working capital of $1,837,150. As of March 31, 2020, the Company has not yet generated any revenues, and has incurred cumulative net losses of $2,781,800. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company is aware that its current cash on hand will not be sufficient to fund its projected operating requirements through the month of June 2020, and is pursuing alternative opportunities to funding. The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. The Company's management do not foresee that COVID-19 has any impact for the Company and its ability to carry out their plans. Accordingly, the accompanying consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the consolidated financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty.

Accounts Payables and Accrued E

Accounts Payables and Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2020
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 3 – ACCOUNTS PAYABLES AND ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES On March 31, 2020, there was $116,000 in accounts payable to related parties in form of payroll and accrued expenses. On December 31, 2019 there was $96,000 in Accounts payable to related parties. The following table represents the major components of accounts payables and accrued expenses and other current liabilities at March 31, 2020 and December 31, 2019: March 31, December 31, Accounts payable related party (1) $ 116,000 $ 96,000 Professional fees 30,973 42,963 Interest 13,982 14,374 Payroll taxes - 7,344 Other accounts payable 1,391 7,251 ASC 480 debt premium 856,560 24,121 Convertible notes payable 862,135 826,862 Total $ 1,881,041 $ 1,018,915 (1) $58,000 to each the CFO and the CEO for 11 months of salary for the period ending March 31 2020, and $48,000 to each the CFO and the CEO for 8 months of salary for the period ending December 31, 2019.

Convertible Notes Payable

Convertible Notes Payable	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
CONVERTIBLE NOTES PAYABLE	NOTE 4 – CONVERTIBLE NOTES PAYABLE As long as the following convertible notes remain outstanding, the Company is restricted from incurring any indebtedness or liens, except as permitted (as defined), and cannot amend its charter in any matter that materially effects rights of noteholders, repay or repurchase more than de minimis number of shares of common stock other than conversion or warrant shares, repay or repurchase all or any portion of any indebtedness, or pay cash dividends. Auctus Note #1 On October 24, 2019 (the "Date of Issuance") the Company issued a convertible promissory note (the "Auctus Note #1") with a face value of $250,000, maturing on October 23, 2020, and a stated interest of 8% to a third-party investor. The Auctus Note #1 is convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Auctus Note #1, or (ii) upon effective date of a registration statement. The conversion price of the Auctus Note #1 is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #1 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Auctus Note #1 was funded on October 29, 2019, when the Company received proceeds of $222,205, after disbursements for the lender's transaction costs, fees and expenses which in aggregate resulted in a total discount of $27,795 to be amortized to interest expense over the life of the Auctus Note #1. Additionally, the variable conversion rate component requires that the Auctus Note #1 be valued at its stock redemption value (i.e., "if-converted" value) pursuant to ASC 480, Distinguishing Liabilities from Equity Along with the Auctus Note #1, on the Date of Issuance the Company issued 208,333 Common Stock Purchase Warrants (the "Warrants"), exercisable immediately at a fixed exercise price of $0.60 with an expiration date of October 23, 2023. The Company has determined that the Warrants are exempt from derivative accounting and were valued at $101,937 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.49 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 251% and (5) risk free interest rate of 2.51%. The note proceeds of $250,000 were then allocated between the fair value of the Auctus Note #1 ($250,000) and the Warrants ($101,937), resulting in a debt discount of $72,412. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance The Auctus Note #1 was paid off on October 24, 2019, and the warrants were converted on March 12,2020 Auctus Note #2 On Additionally, the variable conversion rate component requires that the Auctus Note #2 be valued at its stock redemption value (i.e., "if-converted" value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the Auctus Note #2. As such, the Company recorded a premium of $82,500 as a reduction to additional paid-in capital based on a discounted "if-converted" rate of $0.20 per share (lowest trading price during the 20 days preceding the note's issuance), which computed to 1,250,000 shares of 'if-converted' common stock with a redemption value of $332,500 due to $0.266 per share fair market value of the Company's stock on the Auctus Note #2's date of issuance. Debt discount amortization is recorded as interest expense, while debt premium accretion is recorded as an increase to additional paid-in capital. For the three months ending at March 31, 2020, the Company amortized $4,647 debt discount to operations as interest expense, and accreted $24,121 of premium to additional paid-in capital. Along The Auctus Note #2 was paid off on February 20, 2020, and the warrants were converted on March 12,2020. Other notes currently convertible In the period October 24, 2019 through February 18, 2020, the Company entered into three separate Secured Promissory Note Agreements ("SPA") with a face value of $300,000, and received net proceeds of $255,000. The Notes are convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $37,100 is amortized over the duration of the loans. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity. For the three months ended at March 31, 2020, the Company amortized $6,415 debt discount to operations as interest expense. Additionally, The Company also issued the noteholders five-year warrants with cashless exercise provisions to purchase a total of 122,000 shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions to four of the Lenders. The Company has determined that the Warrants are exempt from derivative accounting. The note proceeds of $300,000 were then allocated between the fair value of the Notes ($300,000) and the Warrants ($55,061), resulting in a debt discount of resulting in a fully amortized debt discount of $34,317. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. For the three months ending at March 31, 2020, the Company issued 72,000 warrants, resulting in an amortized debt discount of $12,711. Notes not yet convertible In the period October 23, 2019 through March 18, 2020, the Company entered into seven separate Secured Promissory Note Agreements ("SPA") with a face value of $636,800, and received net proceeds of $563,500. The Notes are convertible into common stock of the Company, par value $.001 per share (the "Common Stock") at any time after the earlier of: (i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $73,300 is amortized over the duration of the loans. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity. For the three months ended at March 31, 2020, the Company amortized $12,261 debt discount to operations as interest expense. The Company also issued the noteholders five-year warrants with cashless exercise provisions to purchase a total of 150,000 shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions to four of the Lenders. The Company has determined that the Warrants are exempt from derivative accounting. The note proceeds of $636,800 were then allocated between the fair value of the Notes ($636,800) and the Warrants ($97,850), resulting in a debt discount of resulting in a fully amortized debt discount of $68,910. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance. For the three months ending at March 31, 2020, the Company did not issue any warrants. A summary of the outstanding notes at March 31, 2020, are as follows: Debtor Date of Maturity Principal Net Interest Warrants Issued Term Exercise Amortization Debt GS Capital 10/30/2019 10/30/2020 $ 125,000 $ 109,500 4 % 50,000 5 $ 2.00 $ 23,867 $ 15,500 Power Up #1 10/24/2019 10/23/2020 106,000 100,000 8 % - - - - 6,000 Peak One 10/23/2019 10/22/2022 120,000 103,000 0 % 50,000 5 2.00 21,606 17,000 Tangiers 10/23/2019 10/22/2020 106,300 100,000 8 % 50,000 5 2.00 21,116 6,300 FirstFire 11/20/2019 11/20/2020 125,000 109,500 4 % 50,000 5 2.00 17,979 15,500 Power Up #2 12/30/2019 12/30/2020 54,600 50,000 8 % - - - - 4,600 EMA Financial 01/10/2020 01/10/2021 125,000 109,500 4 % 50,000 5 2.00 5,948 15,500 Crown Bridge 02/20/2020 02/20/2021 55,000 42,500 4 % 22,000 5 2.00 10,054 12,500 PowerUp #3 02/19/2020 02/19/2021 56,600 52,000 8 % - - - - 4,600 PowerUp #4 03/18/2020 03/18/2021 64,900 60,000 8 % - - - - 4,900 $ 938,400 $ 836,000 272,000 $ 100,570 $ 102,400 Convertible notes payable consists of the following at March 31, 2020 and December 31, 2019: March 31, 2020 December 31, 2019 Principal balance $ 938,400 $ 886,900 Unamortized debt discount (76,265 ) (60,038 ) Unamortized debt premium 856,560 24,121 Outstanding, net of debt discount and premium $ 1,718,695 $ 850,983

Stockholders_ Equity

Stockholders’ Equity	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 5 – STOCKHOLDERS' EQUITY At a Board of Director's Meeting on July 30, 2019, the Company authorized a reverse split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective on August 13, 2019, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital. As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock. The reverse split has been retroactively applied to all periods presented. Preferred stock As of March 31, 2020, no preferred shares have been designated nor issued. Common stock On January 3, 2020, 100,000 shares of common stock were issued as a result of conversion of accrued interest and principal on the Auctus Note #2 for a total of $12,000. On February 18, 2020, 250,000 shares of common stock were issued as a result of conversion of accrued interest and principal on the Auctus Note #2 for a total of $22,132. On March 12, 2020, 750,000 of common stock were issued in exchange for 416,666 warrants with cashless exercise, originating from Auctus Notes #1 and #2. For the 3 months ending March 31, 2020, 656,000 shares were awarded with an average cost per share of $0.22, under the 2010 Stock Plan for a total value of $150,497. For details, see Shares Awarded and Issued under Note 6. As of March 31, 2020, the Company has 88,231,673 shares of common stock issued and outstanding. At December 31, 2019 there were 86,475,673 shares of common stock issued and outstanding. Common Stock Warrants During the three months ending March 31, 2020 the Company awarded 405,334 warrants, valued at $145,438, and 750,000 warrants were converted in a cashless exercise. During the 3 months ending March 31, 2019 the Company awarded 208,333 warrants valued at $45,361. The following table summarizes the Company's common stock warrant activity for the 3-months ended March 31, 2020 and March 31, 2019: Weighted Average Weighted- Warrants Exercise Expected Outstanding as of January 1, 2019 208,333 $ 0.60 4.6 Granted 208,333 0.60 4.9 Exercised - - - Forfeited/Canceled - -  - Outstanding as of March 31, 2019 416,666 $ 0.60 4.7 Outstanding as of January 1, 2020 616,666 $ 1.05 4.0 Granted 405,334 0.36 0.9 Exercised (750,000 ) - - Forfeited/Canceled - - - Outstanding as of March 31, 2020 272,000 $ 2.00 4.7 During the three months ending March 31, 2020, the Company awarded 48,000 options under the 2010 Stock Plan, with a fair market value of $5,004. There were no options awarded during the 3 months ending March 31, 2019. The following table summarizes the Company's common stock option activity for the 3 months ended at March 31, 2020. There were no stock options issued at March 31, 2019: Weighted Weighted- Number of Options Exercise Expected Outstanding as of January 1, 2020 341,000 $ 0.96 2.4 Granted 48,000 0.16 2.8 Exercised - - - Forfeited/Canceled - - - Outstanding as of March 31, 2020 389,000 $ 0.86 2.5

Stock Option Plan and Stock-Bas

Stock Option Plan and Stock-Based Compensation	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
STOCK OPTION PLAN AND STOCK-BASED COMPENSATION	NOTE 6 – STOCK OPTION PLAN AND STOCK-BASED COMPENSATION During the year ended December 31, 2010, the Company adopted a stock option plan entitled "The 2010 Stock Plan" (2010 Plan) under which the Company may grant Options to Purchase Stock, Stock Awards or Stock Appreciation Rights up to 15% of common stock, automatically adjusted on January 1 each year. As of December 31, 2018, there were no outstanding awards under the 2010 Plan. As of December 31, 2019, there were 341,000 outstanding stock options with a fair market value of $257,143 and 1,127,000 shares issued with a fair market value of $864,551 at the time of award. At December 31, 2018, there were no outstanding stock options, nor any shares awarded. Under the terms of the stock plans, the Board of Directors shall specify the exercise price and vesting period of each stock option on the grant date. Vesting of the options is typically immediate and the options typically expire in five years. Stock Awards may be directly issued under the Plan (without any intervening options). Stock Awards may be issued which are fully and immediately vested upon issuance. Shares Awarded and Issued: On January 1, 2020 the Company granted 250,000 shares with a fair market value of $0.285/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $71,250. On January 31, 2020 the Company granted two subcontractors a total of 200,000 shares with a fair market value of $0.14/share at the time of award, as compensation for their work with the Company's marketing efforts, for a total of $28,000. On March 18, 2020 the Company granted 200,000 shares with a fair market value of $0.245/share at the time of award, to a consultant for assistance with the Companies PR work, for a total of $49,000. On February 21, 2020 the Company granted 3,000 shares with a fair market value of $0.439/share to three members of the Audit Committee as compensation for their contribution in the Audit Committee, for a total of $1,317. On March 25, 2019, the Company granted 3,000 shares with a fair market value of $0.31/share to three members of the Company Board as compensation for their contribution in the Company's Board of Directors, for a total of $930. Number of Shares Fair Value Weighted Shares Issued as of December 31, 2019 471,000 $ 0.27 - 1.49 $ 0.77 Shares Issued 656,000 0.14 – 0.44 0.22 Shares Issued as of March 31, 2020 1,127,000 $ 0.14 - 1.49 $ 0.57 For the three months ended March 31, 2020, the Company recorded stock-based compensation expense of $150,497 in connection with share-based payment awards. The Company did not record any recorded stock-based compensation expense in the three first months of 2019. Stock options granted and vested: On January 1, 2020 the Company granted 3,000 three-year options at an exercise price of $0.31 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $603. On February 1, 2020 the Company granted 45,000 three-year options at an exercise price of $0.15 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of award was $4,401. The fair value of stock options granted and revaluation of non-employee consultant options for the three months ended March 31, 2020 was calculated with the following assumptions: 2020 Risk-free interest rate 1.32 – 1.69 % Expected dividend yield 0 % Volatility factor (weekly) 126.37 % Expected life of option 3 years For the three months ended March 31, 2020, the Company recorded compensation expense of $5,004 in connection with awarded stock options. The Company did not record any awarded option valuation as compensation expense during the three months ended March 31, 2019. As at March 31, 2020, there was no unrecognized compensation expense related to non-vested stock option awards. The following table summarizes the Company's stock option activity for the three months ended March 31, 2020: Number of Options Exercise Weighted Outstanding as of December 31, 2019 341,000 $ 0.61 - 1.21 $ 0.96 Granted 48,000 0.15 - 0.31 0.16 Exercised - - - Options forfeited/cancelled - - - Outstanding as of March 31, 2020 389,000 $ 0.15 - 1.21 $ 0.76 The following table summarizes information about stock options that are vested or expected to vest at March 31, 2020: Options Outstanding Exercisable Options Exercise Number of Options Weighted Average Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic $ 0.15 45,000 $ 0.15 2.84 $ - 45,000 $ 0.15 2.84 $ - 0.31 3,000 0.31 2.75 - 3,000 0.31 2.75 - 0.61 45,000 0.61 2.59 - 45,000 0.61 2.59 - 0.73 3,000 0.73 2.50 - 3,000 0.73 2.50 - 0.95 200,000 0.95 2.45 - 200,000 0.95 2.45 - 1.09 3,000 1.09 2.25 - 3,000 1.09 2.25 - 1.10 45,000 1.10 2.33 - 45,000 1.10 2.33 - 1.21 45,000 1.21 2.08 - 45,000 1.21 2.08 - $ 0.15-1.21 389,000 $ 0.86 2.46 $ - 389,000 $ 0.86 2.46 $ - The following table sets forth the status of the Company's non-vested stock options as of March 31, 2020 and December 31, 2019: Number of Weighted- Non-vested as of December 31, 2019 - $ - Granted 48,000 0.16 Forfeited - - Vested 48,000 0.16 Non-vested as of March 31, 2020 - $ - The weighted-average remaining estimated life for options exercisable at March 31, 2020 is 2.46 years. The aggregate intrinsic value for fully vested, exercisable options was $0 at March 31, 2020. The aggregate intrinsic value of options exercised for the three months ended at March 31, 2020 was $0 as no options were exercised. The actual tax benefit realized from stock option exercises for the three months ended at December 31, 2019 was no options available for exercise. At March 31, 2020 the Company has 10,799,351 options or stock awards available for grant under the 2010 Plan.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 – COMMITMENTS AND CONTINGENCIES Employment contracts The Company's executive officers have entered employment contracts and confidentiality, non-disclosure and assignment of invention agreements. The employment agreements do not provide for the payment of any compensation to our executive officers but provide for the payment of $100,000 in severance upon termination of employment without cause and make no provisions for any payment upon a change of control. Litigation In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. Legal fees for such matters are expensed as incurred and we accrue for adverse outcomes as they become probable and estimable.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS On April 16, 2020 SEC ordered, pursuant to Section 12(k) of the Securities Exchange Act of 1934, that trading of BIXT is suspended for the period April 16, through April 29, 2020. As a result of the SEC ordered suspension the Company defaulted on outstanding Convertible Notes; resulting in an increase of the interest to 21% and the principal to increase to 168% of principal loan amount. The convertible debt increased to approximately $1,604,856 and the interest accrual to approximately $28,960/month. The variable conversion rate component requires that the Defaulted Notes be valued at its stock redemption value (i.e., "if-converted" value) pursuant to ASC 480, Distinguishing Liabilities from Equity The Company's management is taking all reasonable steps to get the Company traded on the OTCQB exchange again, in accordance with regulations as outlined by the SEC, see further: https://www.sec.gov/oiea/investor-alerts-and-bulletins/ib_tradingsuspensions https://www.sec.gov/investor/alerts/tradingsuspensions.pdf Stock options and shares granted under the 2010 Stock Plan: On April 1, 2020 the Company granted 3,000 three-year options at an exercise price of $0.32 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of the award was $646. On May 1, 2020 the Company granted 45,000 three-year options at an exercise price of $0.001 a Medical Advisory Board Member for his contribution in the Company's Advisory Board. The options total fair value at the time of the award was $45. On May 1, 2020 the Company appointed Mr. Mike Sheikh as EVP of Business Development. Mr. Sheikh is committed on a full-time basis. He currently has a compensation of $6,000 per month. The employment agreement provides for the payment of $100,000 in severance upon termination of employment without cause and make no provisions for any payment upon a change of control. Mr. Sheikh was issued 8,800,000 shares to be equally vested over a period of 3 years, but fully vested upon a change of control. The shares total fair value at the time of the award was $8,800. The Company's management has evaluated events occurring after the date of the accompanying balance sheets through the date the financial statements were available to be issued and did not identify any further subsequent events requiring disclosure.

Accounts Payables and Accrued_2

Accounts Payables and Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2020
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
Schedule of accounts payables and accrued expenses and other current liabilities	March 31, December 31, Accounts payable related party (1) $ 116,000 $ 96,000 Professional fees 30,973 42,963 Interest 13,982 14,374 Payroll taxes - 7,344 Other accounts payable 1,391 7,251 ASC 480 debt premium 856,560 24,121 Convertible notes payable 862,135 826,862 Total $ 1,881,041 $ 1,018,915 (1) $58,000 to each the CFO and the CEO for 11 months of salary for the period ending March 31 2020, and $48,000 to each the CFO and the CEO for 8 months of salary for the period ending December 31, 2019.

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2020
Debt Disclosure [Abstract]
Schedule of outstanding notes	Debtor Date of Maturity Principal Net Interest Warrants Issued Term Exercise Amortization Debt GS Capital 10/30/2019 10/30/2020 $ 125,000 $ 109,500 4 % 50,000 5 $ 2.00 $ 23,867 $ 15,500 Power Up #1 10/24/2019 10/23/2020 106,000 100,000 8 % - - - - 6,000 Peak One 10/23/2019 10/22/2022 120,000 103,000 0 % 50,000 5 2.00 21,606 17,000 Tangiers 10/23/2019 10/22/2020 106,300 100,000 8 % 50,000 5 2.00 21,116 6,300 FirstFire 11/20/2019 11/20/2020 125,000 109,500 4 % 50,000 5 2.00 17,979 15,500 Power Up #2 12/30/2019 12/30/2020 54,600 50,000 8 % - - - - 4,600 EMA Financial 01/10/2020 01/10/2021 125,000 109,500 4 % 50,000 5 2.00 5,948 15,500 Crown Bridge 02/20/2020 02/20/2021 55,000 42,500 4 % 22,000 5 2.00 10,054 12,500 PowerUp #3 02/19/2020 02/19/2021 56,600 52,000 8 % - - - - 4,600 PowerUp #4 03/18/2020 03/18/2021 64,900 60,000 8 % - - - - 4,900 $ 938,400 $ 836,000 272,000 $ 100,570 $ 102,400
Schedule of convertible notes payable	March 31, 2020 December 31, 2019 Principal balance $ 938,400 $ 886,900 Unamortized debt discount (76,265 ) (60,038 ) Unamortized debt premium 856,560 24,121 Outstanding, net of debt discount and premium $ 1,718,695 $ 850,983

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2020
Equity [Abstract]
Schedule of company's common stock warrants activity	Weighted Average Weighted- Warrants Exercise Expected Outstanding as of January 1, 2019 208,333 $ 0.60 4.6 Granted 208,333 0.60 4.9 Exercised - - - Forfeited/Canceled - -  - Outstanding as of March 31, 2019 416,666 $ 0.60 4.7 Outstanding as of January 1, 2020 616,666 $ 1.05 4.0 Granted 405,334 0.36 0.9 Exercised (750,000 ) - - Forfeited/Canceled - - - Outstanding as of March 31, 2020 272,000 $ 2.00 4.7 Weighted Weighted- Number of Options Exercise Expected Outstanding as of January 1, 2020 341,000 $ 0.96 2.4 Granted 48,000 0.16 2.8 Exercised - - - Forfeited/Canceled - - - Outstanding as of March 31, 2020 389,000 $ 0.86 2.5

Stock Option Plan and Stock-B_2

Stock Option Plan and Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Summary of fair value of stock awards granted	Number of Shares Fair Value Weighted Shares Issued as of December 31, 2019 471,000 $ 0.27 - 1.49 $ 0.77 Shares Issued 656,000 0.14 – 0.44 0.22 Shares Issued as of March 31, 2020 1,127,000 $ 0.14 - 1.49 $ 0.57
Summary of stock options granted valuation assumptions	2020 Risk-free interest rate 1.32 – 1.69 % Expected dividend yield 0 % Volatility factor (weekly) 126.37 % Expected life of option 3 years
Summary of stock option activity	Number of Options Exercise Weighted Outstanding as of December 31, 2019 341,000 $ 0.61 - 1.21 $ 0.96 Granted 48,000 0.15 - 0.31 0.16 Exercised - - - Options forfeited/cancelled - - - Outstanding as of March 31, 2020 389,000 $ 0.15 - 1.21 $ 0.76
Summary of stock options vested or expected to vest	Options Outstanding Exercisable Options Exercise Number of Options Weighted Average Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Number of Options Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic $ 0.15 45,000 $ 0.15 2.84 $ - 45,000 $ 0.15 2.84 $ - 0.31 3,000 0.31 2.75 - 3,000 0.31 2.75 - 0.61 45,000 0.61 2.59 - 45,000 0.61 2.59 - 0.73 3,000 0.73 2.50 - 3,000 0.73 2.50 - 0.95 200,000 0.95 2.45 - 200,000 0.95 2.45 - 1.09 3,000 1.09 2.25 - 3,000 1.09 2.25 - 1.10 45,000 1.10 2.33 - 45,000 1.10 2.33 - 1.21 45,000 1.21 2.08 - 45,000 1.21 2.08 - $ 0.15-1.21 389,000 $ 0.86 2.46 $ - 389,000 $ 0.86 2.46 $ -
Summary of non-vested stock options	Number of Weighted- Non-vested as of December 31, 2019 - $ - Granted 48,000 0.16 Forfeited - - Vested 48,000 0.16 Non-vested as of March 31, 2020 - $ -

Background and Organization (De

Background and Organization (Details) - $ / shares	Mar. 31, 2020	Dec. 31, 2019	Sep. 21, 2019	Oct. 05, 2017
Background and Organization (Textual)
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Delaware [Member]
Background and Organization (Textual)
Common stock, par value			$ 0.001	$ 0.0001
Common stock, shares authorized			300,000,000	95,000,000
Preferred stock, par value			$ 0.001	$ 0.0001
Preferred stock, shares authorized			50,000,000	5,000,000

Going Concern and Management'_2

Going Concern and Management's Liquidity Plans (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Going Concern and Management's Liquidity Plans (Textual)
Cash	$ 43,891	$ 169,628	$ 118,931	$ 36,411
Negative working capital	1,837,150
Cumulative net losses	$ 2,781,800	$ 2,241,305

Accounts Payables and Accrued_3

Accounts Payables and Accrued Expenses and Other Current Liabilities (Details) - USD ($)		Mar. 31, 2020	Dec. 31, 2019
Accounts Payables and Accrued Expenses and Other Current Liabilities [Abstract]
Accounts payable related party	[1]	$ 116,000	$ 96,000
Professional fees		30,973	42,963
Interest		13,982	14,374
Payroll taxes			7,344
Other accounts payable		1,391	7,251
ASC 480 debt premium		856,560	24,121
Convertible notes payable		1,718,695	850,983
Total		$ 1,881,041	$ 1,018,915
[1]	$58,000 to each the CFO and the CEO for 11 months of salary for the period ending March 31 2020, and $48,000 to each the CFO and the CEO for 8 months of salary for the period ending December 31, 2019.

Accounts Payables and Accrued_4

Accounts Payables and Accrued Expenses and Other Current Liabilities (Details Textual) - USD ($)	8 Months Ended	11 Months Ended
	Dec. 31, 2019	Mar. 31, 2020
Accounts Payables and Accrued Expenses and Other Current Liabilities (Textual)
Accrued expenses in accounts payables to related parties	$ 96,000	$ 116,000
CFO [Member]
Accounts Payables and Accrued Expenses and Other Current Liabilities (Textual)
Accrued salary expenses	$ 48,000	$ 58,000
Duration of accrued salary paid	8 months	11 months
CEO [Member]
Accounts Payables and Accrued Expenses and Other Current Liabilities (Textual)
Accrued salary expenses	$ 48,000	$ 58,000
Duration of accrued salary paid	8 months	11 months

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Principal Amount	$ 938,400
Net Received	$ 836,000
Warrants Issued	272,000
Amortization of Warrants	$ 100,570
Debt Discount	$ 166,722	$ 54,897
GS Capital [Member]
Debtor	GS Capital
Date of Issuance	Oct. 30, 2019
Maturity Date	Oct. 30, 2020
Principal Amount	$ 125,000
Net Received	$ 109,500
Interest	4.00%
Warrants Issued	50,000
Term	5 years
Exercise Price	$ 2
Amortization of Warrants	$ 23,867
Debt Discount	$ 15,500
Power Up #1 [Member]
Debtor	Power Up
Date of Issuance	Oct. 24, 2019
Maturity Date	Oct. 23, 2020
Principal Amount	$ 106,000
Net Received	$ 100,000
Interest	8.00%
Warrants Issued
Exercise Price
Amortization of Warrants
Debt Discount	$ 6,000
Peak One [Member]
Debtor	Peak One
Date of Issuance	Oct. 23, 2019
Maturity Date	Oct. 22, 2022
Principal Amount	$ 120,000
Net Received	$ 103,000
Interest	0.00%
Warrants Issued	50,000
Term	5 years
Exercise Price	$ 2
Amortization of Warrants	$ 21,606
Debt Discount	$ 17,000
Tangiers [Member]
Debtor	Tangiers
Date of Issuance	Oct. 23, 2019
Maturity Date	Oct. 22, 2020
Principal Amount	$ 106,300
Net Received	$ 100,000
Interest	8.00%
Warrants Issued	50,000
Term	5 years
Exercise Price	$ 2
Amortization of Warrants	$ 21,116
Debt Discount	$ 6,300
FirstFire [Member]
Debtor	FirstFire
Date of Issuance	Nov. 20, 2019
Maturity Date	Nov. 20, 2020
Principal Amount	$ 125,000
Net Received	$ 109,500
Interest	4.00%
Warrants Issued	50,000
Term	5 years
Exercise Price	$ 2
Amortization of Warrants	$ 17,979
Debt Discount	$ 15,500
Power Up #2 [Member]
Debtor	Power Up
Date of Issuance	Dec. 30, 2019
Maturity Date	Dec. 30, 2020
Principal Amount	$ 54,600
Net Received	$ 50,000
Interest	8.00%
Warrants Issued
Exercise Price
Amortization of Warrants
Debt Discount	$ 4,600
EMA Financial [Member]
Debtor	EMA Financial
Date of Issuance	Jan. 10, 2020
Maturity Date	Jan. 10, 2021
Principal Amount	$ 125,000
Net Received	$ 109,500
Interest	4.00%
Warrants Issued	50,000
Term	5 years
Exercise Price	$ 2
Amortization of Warrants	$ 5,948
Debt Discount	$ 15,500
Crown Bridge [Member]
Debtor	Crown Bridge
Date of Issuance	Feb. 20, 2020
Maturity Date	Feb. 20, 2021
Principal Amount	$ 55,000
Net Received	$ 42,500
Interest	4.00%
Warrants Issued	22,000
Term	5 years
Exercise Price	$ 2
Amortization of Warrants	$ 10,054
Debt Discount	$ 12,500
PowerUp #3 [Member]
Debtor	PowerUp #3
Date of Issuance	Feb. 19, 2020
Maturity Date	Feb. 19, 2021
Principal Amount	$ 56,600
Net Received	$ 52,000
Interest	8.00%
Warrants Issued
Exercise Price
Amortization of Warrants
Debt Discount	$ 4,600
Power Up3 [Member]
Debtor	PowerUp #4
Date of Issuance	Mar. 18, 2020
Maturity Date	Mar. 18, 2021
Principal Amount	$ 64,900
Net Received	$ 60,000
Interest	8.00%
Warrants Issued
Exercise Price
Amortization of Warrants
Debt Discount	$ 4,900

Convertible Notes Payable (De_2

Convertible Notes Payable (Details 1) - USD ($)	Mar. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Unamortized debt premium	$ 856,560	$ 24,121
Convertible notes payable [Member]
Principal balance	938,400		$ 886,900
Unamortized debt discount	(76,265)		(60,038)
Unamortized debt premium	856,560		24,121
Outstanding, net of debt discount and premium	$ 1,718,695		$ 850,983

Convertible Notes Payable (De_3

Convertible Notes Payable (Details Textual) - USD ($)	Mar. 12, 2020	Feb. 25, 2020	Feb. 18, 2020	Jan. 03, 2020	Oct. 24, 2019	Oct. 23, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Convertible Notes Payable (Textual)
Common stock per share							$ 0.001		$ 0.001
Principal balance							$ 938,400
Interest expense							107,730	$ 6,887
Additional paid-in capital							856,418		$ 1,355,542
Additional Warrant issued	$ 166,667
Fair value amount	$ 66,364
Amortized debt discount							$ 100,570
Auctus Note #1 [Member]
Convertible Notes Payable (Textual)
Common stock per share					$ 0.001
Expiration date					Oct. 23, 2019
Convertible note, description					(i) 180 days from the date of the Auctus Note #1, or (ii) upon effective date of a registration statement. The conversion price of the Auctus Note #1 is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #1 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Auctus Note #1 was funded on October 29, 2019, when the Company received proceeds of $222,205, after disbursements for the lender's transaction costs, fees and expenses which in aggregate resulted in a total discount of $27,795 to be amortized to interest expense over the life of the Auctus Note #1.
Determined warrants derivative, description					The Company has determined that the Warrants are exempt from derivative accounting and were valued at $101,937 on the Date of Inception using the Black Scholes Options Pricing Model.  Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.49 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 251% and (5) risk free interest rate of 2.51%.  The note proceeds of $250,000 were then allocated between the fair value of the Auctus Note #1 ($250,000) and the Warrants ($101,937), resulting in a debt discount of $72,412.
Principal balance					$ 250,000
Stated interest					8.00%
Debt premium					$ 343,796
Common stock purchase warrants issued					208,333
Auctus Note #1 [Member] | Convertible notes payable [Member]
Convertible Notes Payable (Textual)
Common stock per share					$ 0.001
Expiration date					Oct. 23, 2023
Convertible note, description					"if-converted" rate of $0.21 per share (65% of the average of the three lowest trading prices during the 20 days preceding the note's issuance), which computed to 1,211,828 shares of 'if-converted' common stock with a redemption value of $593,796 due to $0.49 per share fair market value of the Company's stock on the Auctus Note #1's date of issuance. Debt discount amortization is recorded as interest expense, while debt premium amortization is recorded as an increase to additional paid-in capital.
Warrants exercise price					$ 0.60
Auctus Note #2 [Member]
Convertible Notes Payable (Textual)
Common stock per share		$ 0.60
Expiration date		Feb. 24, 2024
Convertible note, description		The variable conversion rate component requires that the Auctus Note #2 be valued at its stock redemption value (i.e., “if-converted” value) pursuant to ASC 480, Distinguishing Liabilities from Equity, with the excess over the undiscounted face value being deemed a premium to be added to the principal balance and accreted to additional paid-in capital over the life of the Auctus Note #2. As such, the Company recorded a premium of $82,500 as a reduction to additional paid-in capital based on a discounted “if-converted” rate of $0.20 per share (lowest trading price during the 20 days preceding the note’s issuance), which computed to 1,250,000 shares of ‘if-converted’ common stock with a redemption value of $332,500 due to $0.266 per share fair market value of the Company’s stock on the Auctus Note #2’s date of issuance. Debt discount amortization is recorded as interest expense, while debt premium accretion is recorded as an increase to additional paid-in capital.
Determined warrants derivative, description		The Company has determined that the Warrants are exempt from derivative accounting and were valued at $55,417 on the Date of Inception using the Black Scholes Options Pricing Model. Assumptions used for the Black Scholes Options Pricing Model include (1) stock price of $0.27 per share, (2) exercise price of $0.60 per share, (3) term of 5 years, (4) expected volatility of 323% and (5) risk free interest rate of 2.56%. The Auctus Note #2 proceeds of $250,000 were then allocated between the fair value of the Auctus Note #2 ($250,000) and the Warrants ($55,417), resulting in a debt discount of $45,361.
Common stock purchase warrants issued		208,333	250,000	100,000			72,000
Interest expense							$ 4,647
Amortized debt discount							12,711
Premium to additional paid-in capital							24,121
Auctus Note #2 [Member] | Secured Promissory Note [Member]
Convertible Notes Payable (Textual)
Convertible notes issued		$ 27,750
Common stock per share		$ 0.001
Expiration date		Feb. 24, 2020
Convertible note, description		(i) 180 days from the date of the Auctus Note #2 or (ii) upon effective date of a new registration statement. The conversion price of the Auctus Note #2 is equal to the lesser of : (i) the lowest trading price for the twenty-day period prior to the date of the Auctus Note #2 or (ii) 65% of the average of the three lowest trading prices during the twenty days prior to a conversion notice on the applicable trading market or the closing bid price on the applicable trading market. The Company may prepay the Auctus Note #2 at any time at a rate of 120% of outstanding principal and interest during the first 90 days it is outstanding and 130% of outstanding principal and interest for the next 90 days thereafter. Thereafter the prepayment amount increases 5% for each thirty-day period until 270 days from the issue date at which time it is fixed at 150% of the outstanding principal and interest on the Auctus Note #2.
Principal balance		$ 250,000
Stated interest		8.00%
Net proceeds		$ 222,250
Other Notes Currently Convertible [Member]
Convertible Notes Payable (Textual)
Convertible note, description					“if-converted” rate between $0.091- $0.12 per share (65% of the average of the three lowest trading prices during the 20 days preceding the note’s issuance), which computed to 2,962,578 shares of ‘if-converted’ common stock with a redemption value of $1,237,007 due to in between $0.265- $0.50 per share fair market value of the Company’s stock on the three notes date of issuance. Debt discount amortization is recorded as interest expense, while debt premium amortization is recorded as an increase to additional paid-in capital. For the three months ending at March 31, 2020, the Company amortized $4,376 debt discount to operations as interest expense, and accreted $80,447 of premium to additional paid-in capital.
Determined warrants derivative, description					The Company also issued the noteholders five-year warrants with cashless exercise provisions to purchase a total of 122,000 shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions to four of the Lenders. The Company has determined that the Warrants are exempt from derivative accounting. The note proceeds of $300,000 were then allocated between the fair value of the Notes ($300,000) and the Warrants ($55,061), resulting in a debt discount of resulting in a fully amortized debt discount of $34,317. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance.
Debt premium					$ 937,007
Other Notes Currently Convertible [Member] | Secured Promissory Note [Member]
Convertible Notes Payable (Textual)
Debt discount					$ 37,100
Common stock per share					$ 0.001
Convertible note, description					(i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $37,100 is amortized over the duration of the loans. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity. For the three months ended at March 31, 2020, the Company amortized $6,415 debt discount to operations as interest expense.
Principal balance					$ 300,000
Net proceeds					$ 255,000
Interest expense							$ 6,415
Notes Not Yet Convertible [Member]
Convertible Notes Payable (Textual)
Determined warrants derivative, description						The Company also issued the noteholders five-year warrants with cashless exercise provisions to purchase a total of 150,000 shares of Common Stock of the Company at an exercise price of $2.00 per share with cashless exercise provisions to four of the Lenders. The Company has determined that the Warrants are exempt from derivative accounting. The note proceeds of $636,800 were then allocated between the fair value of the Notes ($636,800) and the Warrants ($97,850), resulting in a debt discount of resulting in a fully amortized debt discount of $68,910. As the warrants were exercisable immediately, this debt discount was amortized in its entirety to interest expense on the Date of Issuance.
Notes Not Yet Convertible [Member] | Secured Promissory Note [Member]
Convertible Notes Payable (Textual)
Debt discount						$ 73,300
Common stock per share						$ 0.001
Convertible note, description						(i) 180 days from the date of the Note or (ii) upon effective date of a registration statement. The conversion price of the Notes is equal to 65% of the lowest trading price at close during the twenty days prior to a conversion notice. The debt discount of $73,300 is amortized over the duration of the loans. The Debentures permit the Company to pre-pay its obligations at a premium prior to maturity. For the three months ended at March 31, 2020, the Company amortized $12,261 debt discount to operations as interest expense.
Principal balance						$ 636,800
Net proceeds						$ 563,500

Stockholders' Equity (Details)

Stockholders' Equity (Details) - $ / shares	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Equity Option [Member]
Number of shares, Outstanding, Beginning balance	341,000
Number of shares, granted	48,000
Number of shares, exercised
Number of shares, Forfeited/Cancelled
Number of shares, Outstanding, Ending balance	389,000
Weighted-Average Exercise Price, Outstanding, Beginning balance	$ 0.96
Weighted-Average Exercise Price, granted	0.16
Weighted-Average Exercise Price, exercised
Weighted-Average Exercise Price, Forfeited/Cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	$ 0.86
Weighted-Average Remaining Expected Term, Beginning balance	2 years 4 months 24 days
Weighted-Average Remaining Expected Term, Options granted	2 years 9 months 18 days
Weighted-Average Remaining Expected Term, Ending balance	2 years 6 months
Warrant [Member]
Number of shares, Outstanding, Beginning balance	616,666	208,333
Number of shares, granted	405,334	208,333
Number of shares, exercised	(750,000)
Number of shares, Forfeited/Cancelled
Number of shares, Outstanding, Ending balance	272,000	416,666
Weighted-Average Exercise Price, Outstanding, Beginning balance	$ 1.05	$ 0.60
Weighted-Average Exercise Price, granted	0.36	0.60
Weighted-Average Exercise Price, exercised
Weighted-Average Exercise Price, Forfeited/Cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	$ 2	$ 0.60
Weighted-Average Remaining Expected Term, Beginning balance	4 years	4 years 7 months 6 days
Weighted-Average Remaining Expected Term, Options granted	10 months 25 days	4 years 10 months 25 days
Weighted-Average Remaining Expected Term, Ending balance	4 years 8 months 12 days	4 years 8 months 12 days

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Mar. 12, 2020	Mar. 12, 2020	Feb. 25, 2020	Feb. 18, 2020	Jan. 03, 2020	Jul. 30, 2019	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019
Stockholders' Equity (Textual)
Description of reverse stock split						The Company authorized a reverse split that resulted in a reduction of the number of outstanding and issued shares of both common and preferred stock so that after the split became effective on August 13, 2019, the shares of both common and preferred stock were reduced to 1 share for each 30 shares currently issued and outstanding. The effect on the Balance Sheet is a transfer of value from stock value at par to Additional Paid-in Capital. As a result of the one (1) for thirty (30) reverse stock split, the Company will continue to be authorized to issue 300,000,000 shares of Common Stock, and 50,000,000 shares of Preferred Stock. The reverse split has been retroactively applied to all periods presented.
Preferred stock, shares issued
Common stock, shares issued							88,231,673	86,475,673
Common stock, shares outstanding							88,231,673	86,475,673
Warrants as part of a convertible note agreement							272,000
Fair market value of warrant		$ 66,364
Warrant [Member]
Stockholders' Equity (Textual)
Share price							$ 2
Warrant							405,334		208,333
Warrant value							$ 145,438		$ 45,361
Warrants converted cashless exercise							750,000
2010 Stock Plan [Member]
Stockholders' Equity (Textual)
Conversion of accrued interest							$ 150,497
Shares issued for conversion of accrued interest, shares							656,000
Share price							$ 0.22
Awarded option							48,000
Fair market value of warrant							$ 5,004
Auctus Note #2 [Member]
Stockholders' Equity (Textual)
Conversion of accrued interest				$ 22,132	$ 12,000
Shares issued for conversion of accrued interest, shares			208,333	250,000	100,000		72,000
Auctus Notes #1 and #2 [Member]
Stockholders' Equity (Textual)
Shares issued for conversion of accrued interest, shares	750,000
Warrants as part of a convertible note agreement	416,666

Stock Option Plan and Stock-B_3

Stock Option Plan and Stock-Based Compensation (Details) - Stock Awards Plan [Member]	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of shares issued, December 31, 2019 | shares	471,000
Number of shares, Shares Issued | shares	656,000
Number of shares issued, March 31, 2020 | shares	1,127,000
Weighted Average Market Value per share, December 31, 2019	$ 0.77
Weighted Average Market Value per Share, Shares issued	0.22
Weighted Average Market Value per Share, march 31, 2020	0.57
Minimum [Member]
Fair value per share of December 31, 2019	0.27
Fair value per share, Shares Issued	0.14
Fair Value per Share, March 31, 2020	0.14
Maximum [Member]
Fair value per share of December 31, 2019	1.49
Fair value per share, Shares Issued	0.44
Fair Value per Share, March 31, 2020	$ 1.49

Stock Option Plan and Stock-B_4

Stock Option Plan and Stock-Based Compensation (Details 1)	3 Months Ended
	Mar. 31, 2020
Share-based Payment Arrangement [Abstract]
Risk-free interest rate, Minimum	1.32%
Risk-free interest rate, Maximum	1.69%
Expected dividend yield	0.00%
Volatility factor (weekly)	126.37%
Expected life of option	3 years

Stock Option Plan and Stock-B_5

Stock Option Plan and Stock-Based Compensation (Details 2) - Stock Option [Member]	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of shares, Outstanding, Beginning balance | shares	341,000
Granted | shares	48,000
Exercised | shares
Options forfeited/cancelled | shares
Number of shares, Outstanding, Ending balance | shares	389,000
Weighted-Average Exercise Price, Outstanding, Beginning balance	$ 0.96
Weighted Average Exercise Price per Share, Granted	0.16
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Options forfeited/cancelled
Weighted-Average Exercise Price, Outstanding, Ending balance	0.76
Minimum [Member]
Exercise Price per Share, Outstanding as of December 31, 2018	0.61
Exercise Price per Share, Granted	0.15
Exercise Price per Share, Exercised
Exercise Price per Share, Options forfeited/cancelled
Exercise Price per Share, Outstanding as of September 30, 2019	0.15
Maximum [Member]
Exercise Price per Share, Outstanding as of December 31, 2018	1.21
Exercise Price per Share, Granted	0.31
Exercise Price per Share, Exercised
Exercise Price per Share, Options forfeited/cancelled
Exercise Price per Share, Outstanding as of September 30, 2019	$ 1.21

Stock Option Plan and Stock-B_6

Stock Option Plan and Stock-Based Compensation (Details 3)	3 Months Ended
	Mar. 31, 2020USD ($)$ / sharesshares
Exercise Price, Lower Range Limit	$ 0.15
Exercise Price, Upper Range Limit	$ 1.21
Options Outstanding, Number of Options | shares	389,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.86
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 5 months 16 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	389,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.86
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 5 months 16 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.15 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.15
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 10 months 3 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.15
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 10 months 3 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.31 [Member]
Options Outstanding, Number of Options | shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.31
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 9 months
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.31
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 9 months
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.61 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.61
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 7 months 2 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.61
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 7 months 2 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.73 [Member]
Options Outstanding, Number of Options | shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.73
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 6 months
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.73
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 6 months
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 0.95 [Member]
Options Outstanding, Number of Options | shares	200,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 0.95
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 5 months 12 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	200,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 0.95
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 5 months 12 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.09 [Member]
Options Outstanding, Number of Options | shares	3,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.09
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 2 months 30 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	3,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.09
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 2 months 30 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.10 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.10
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 3 months 29 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.10
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 3 months 29 days
Exercisable Options, Aggregate Intrinsic Value | $
Exercise Price 1.21 [Member]
Options Outstanding, Number of Options | shares	45,000
Options Outstanding, Weighted Average Exercise Price Per Share	$ 1.21
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	2 years 29 days
Options Outstanding, Aggregate Intrinsic Value | $
Exercisable Options, Number of Options | shares	45,000
Exercisable Options, Weighted Average Exercise Price Per Share	$ 1.21
Exercisable Options, Weighted Average Remaining Contractual Life (Years)	2 years 29 days
Exercisable Options, Aggregate Intrinsic Value | $

Stock Option Plan and Stock-B_7

Stock Option Plan and Stock-Based Compensation (Details 4) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2020$ / sharesshares
Number of Options, Non-vested as of December 31, 2019 | shares
Number of Options, Non-vested Granted | shares	48,000
Number of Options, Non-vested Forfeited | shares
Number of Options, Vested | shares	48,000
Number of Options, Non-vested as of March 31, 2020 | shares
Weighted-Average Grant-Date Fair Value, Non-vested as of December 31, 2019 | $ / shares
Weighted-Average Grant-Date Fair Value, Granted | $ / shares	0.16
Weighted-Average Grant-Date Fair Value, Forfeited | $ / shares
Weighted-Average Grant-Date Fair Value, Vested | $ / shares	0.16
Weighted-Average Grant-Date Fair Value, Non-vested as of March 31, 2020 | $ / shares

Stock Option Plan and Stock-B_8

Stock Option Plan and Stock-Based Compensation (Details Textual)	Feb. 02, 2020USD ($)$ / sharesshares	Jan. 02, 2020USD ($)$ / sharesshares	Mar. 18, 2020USD ($)$ / sharesshares	Feb. 21, 2020USD ($)Persons$ / sharesshares	Jan. 31, 2020USD ($)Persons$ / sharesshares	Mar. 25, 2019USD ($)$ / sharesshares	Mar. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2010
Stock Option Plan and Stock Based Compensation (Textual)
Stock-based compensation expense							$ 150,497
Aggregate intrinsic value of options exercised
Share-based Payment Arrangement, Option [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options outstanding number | shares							389,000	341,000
Options granted | shares							48,000
Grants in period, weighted average grant date fair value | $ / shares							$ 0.16
Stock options exercised | shares
Consultant [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares		250,000	200,000
Grants in period, weighted average grant date fair value | $ / shares		$ 0.285	$ 0.245
Options granted, value		$ 71,250	$ 49,000
Subcontractors [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares					200,000
Grants in period, weighted average grant date fair value | $ / shares					$ 0.14
Number of persons | Persons					2
Options granted, value					$ 28,000
Members Audit Committee [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares				3,000
Grants in period, weighted average grant date fair value | $ / shares				$ 0.439
Number of persons | Persons				3
Options granted, value				$ 1,317
Board of Directors Chairman [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares						3,000
Grants in period, weighted average grant date fair value | $ / shares						$ 0.31
Options granted, value						$ 930
Medical Advisory Board [Member] | Share-based Payment Arrangement, Option [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Options granted | shares	45,000	3,000
Grants in period, weighted average grant date fair value | $ / shares	$ 0.15	$ 0.31
Options granted, value	$ 4,401	$ 603
Terms of award	Three-year options	Three-year options
2010 Stock Plan [Member]
Stock Option Plan and Stock Based Compensation (Textual)
Stock appreciation rights percentage									15.00%
Options outstanding number | shares								341,000
Options granted, value								$ 257,143
Shares issued for services | shares								1,127,000
Shares issued for services, value								$ 864,551
Stock-based compensation expense							$ 5,004
Weighted-average remaining contractual life options exercisable							2 years 5 months 16 days
Aggregate intrinsic value for fully vested, exercisable options							$ 0
Aggregate intrinsic value of options exercised							$ 0
Options or stock awards available for grant under the 2010 Plan | shares							10,799,351

Commitments and Contingencies (

Commitments and Contingencies (Details)	Mar. 31, 2020USD ($)
Commitments and Contingencies (Textual)
Payment of severance upon termination	$ 100,000

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	Apr. 01, 2020	May 01, 2020	Mar. 31, 2020
Subsequent Events (Textual)
Conversion amount increase in percentage			21.00%
Priniciple amount interest rate			168.00%
Convertibel note amount			$ 1,604,856
Interest accural amount per month			28,960
Premium amount			475,598
Payment of severance upon termination			$ 100,000
Subsequent event, description			The Company recorded a premium of $475,598 as a reduction to additional paid-in capital based on a discounted "if-converted" rate of $0.14 per share (65% of the lowest trading price during the 20 days preceding the note's issuance), which computed to 4,454,213 shares of 'if-converted' common stock.
Option term			3 years
Mr. Mike Sheikh [Member]
Subsequent Events (Textual)
Compensation amount per month			$ 6,000
Payment of severance upon termination			$ 100,000
Subsequent event, description			Mr. Sheikh was issued 8,800,000 shares to be equally vested over a period of 3 years, but fully vested upon a change of control. The shares total fair value at the time of the award was $8,800.
2010 Stock Plan [Member]
Subsequent Events (Textual)
Shares issued for conversion of accrued interest, shares			656,000
Subsequent events [Member] | Medical Advisory Board Member [Member] | 2010 Stock Plan [Member]
Subsequent Events (Textual)
Granted shares	3,000	45,000
Option term	3 years	3 years
Exercise price	$ 0.32	$ 0.001